Ebola Vaccines
Viral vector vaccines
This page catalogs 2 Ebola vaccine products. The development of Ebola vaccines accelerated dramatically during the 2014–2016 West Africa epidemic, leading to the first FDA-approved Ebola vaccine (ERVEBO) in 2019. Both products use viral vector technology.
Last updated: April 2026.
Ebola Vaccine Catalog
| Trade Name | Generic Designation | Manufacturer | Vaccine Type | Regulatory Status & Year | Key Notes |
|---|---|---|---|---|---|
| ERVEBO | Ebola Zaire vaccine, live (rVSV-ZEBOV) | Merck | Live recombinant viral vector | FDA Licensed, 2019 | First FDA-approved Ebola vaccine |
| Zabdeno + Mvabea | Ad26.ZEBOV + MVA-BN-Filo (2-dose regimen) | Janssen/Bavarian Nordic | Adenovirus vector + MVA | EMA Authorized, 2020 | Heterologous 2-dose Ebola regimen |
Sources
Regulatory data sourced from FDA CBER Vaccines Licensed for Use in the United States (March 2026) and EMA Medicines database. Catalog scope informed by Khan, Shaz, The Ultimate Vaccine Timeline.